Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646243 | 0.80 | DPP4 (0.64) | DPP4HPGDALDH1A1EPHX1 | |
| SCHEMBL645605 | 0.79 | DPP4 (0.57) | DPP4HPGDRECQLPTPN2PTPN1 | |
| SCHEMBL16105020 | 0.74 | EPHX1 (0.49) | HPGDGPR119RECQLMEN1KMT2A | |
| SCHEMBL13634197 | 0.73 | EPHX1 (0.48) | HPGDGPR119RECQLMEN1KMT2A | |
| SCHEMBL2079844 | 0.73 | GPR119 (0.49) | HPGDGPR119RECQLMEN1KMT2A | |
| SCHEMBL16993001 | 0.72 | EPHX1 (0.50) | HPGDGPR119RECQLALDH1A1MAPT | |
| SCHEMBL13811514 | 0.71 | GPR119 (0.52) | HPGDGPR119RECQLEPHX1 | |
| SCHEMBL4711418 | 0.71 | HPGD (0.55) | HPGDGPR119RECQLMEN1KMT2A | |
| SCHEMBL13089780 | 0.70 | GPR119 (0.51) | HPGDGPR119RECQLMEN1ALDH1A1 | |
| SCHEMBL16095809 | 0.70 | GPR119 (0.46) | HPGDGPR119RECQLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119664-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885HPGD 1728/4885GPR119 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.